Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.79)
# 1,945
Out of 5,067 analysts
75
Total ratings
43.86%
Success rate
7.64%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $22 → $20 | $23.90 | -16.32% | 17 | May 8, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $20.30 | -26.11% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $14.82 | -46.02% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $23.32 | +114.41% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $141.25 | -3.72% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $5.18 | +208.88% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $10.40 | +496.15% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $1.28 | +837.50% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $18.91 | +476.41% | 3 | Dec 12, 2023 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $8 | $1.70 | +370.59% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.84 | +160.42% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $8.56 | +1,068.22% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $21.87 | -72.57% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $3.65 | +475.34% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $206.93 | -88.89% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $41.95 | -14.18% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
May 8, 2025
Maintains: Hold
Price Target: $22 → $20
Current: $23.90
Upside: -16.32%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $20.30
Upside: -26.11%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $14.82
Upside: -46.02%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $23.32
Upside: +114.41%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $141.25
Upside: -3.72%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $5.18
Upside: +208.88%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $10.40
Upside: +496.15%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $1.28
Upside: +837.50%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $18.91
Upside: +476.41%
Acumen Pharmaceuticals
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $1.70
Upside: +370.59%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.84
Upside: +160.42%
Nov 11, 2022
Maintains: Buy
Price Target: $140 → $100
Current: $8.56
Upside: +1,068.22%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $21.87
Upside: -72.57%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $3.65
Upside: +475.34%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $206.93
Upside: -88.89%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $41.95
Upside: -14.18%